PRIMOLAB

Methenolone is an anabolic steroid. It has a 1-methyl group that works to increase its oral bioavailability. Methenolone Acetate has a double bond in its structure that helps increase its liver resistance to deactivation and improves its bioavailability.

Tablets: Methenolone Acetate;

Inoperable breast carcinoma: As a palliative, secondary, or tertiary treatment of metastatic breast cancer in women with tumors or hormone-sensitive women who have shown a prior response to hormone therapy.

Postmenopausal Osteoporosis.

Injectable: Methenolone Acetate:

Alterations in protein metabolism, with loss of muscle mass and a negative nitrogen balance.

Specific anemia: aplastic anemia myelofibrosis, myelosclerosis, chronic idiopathic myelofibrosis, hypoplastic anemia caused by malignant tumors or myelotoxic drugs.

The following reactions require medical supervision:

Virilization and menstrual irregularities in women, bladder irritability, gynecomastia, anaphylaxis, edema, erythrocytes, gastrointestinal irritation, hypercalcemia and polycythemia, androgenic alopecia, seborrhea and acne in men and women.

Hypertrophic prostatic carcinoma, and increased sexual desire may be developed by some patients.

Virilization (in men: priapism, testicular atrophy, oligospermia, gynecomastia, sexual impotence, decreased libido; in women: hirsutism, acne, hoarseness of the voice, hypertrophy of the clitoris, breast and endometrium, dysmenorrhea atrophy ), cholestatic jaundice; excitability; hypercholesterolemia, hypercalcemia; edema.

Uncommon adverse reactions during long-term or high-dose therapy are: liver necrosis, leukopenia; liver purpura.

Other adverse reactions are: constipation, nausea, diarrhea, infection, redness, pain or irritation at the injection site, changes in libido, stomach pain, sleep disorders, headache, anxiety, depression, generalized paraesthesia, acne.

Hypersensitivity to Methenolone

Concomitant use with oral anticoagulants.

It is contraindicated in confirmed or suspected breast cancer (male), prostate cancer or adenoma. severe heart, liver or kidney failure.

In prepubertal individuals or people in an aggressive state;

Pregnancy, active hypercalcemia.

Interactions with other medications

Concomitant use with oral anticoagulants requires monitoring and adjustment of anticoagulant doses. Concomitant administration with bupropion lowers the detection threshold for systemic steroids.

The tablets should be taken orally in 10 mg to 20 mg doses / day.

IM doses are 100 mg every 1-2 weeks, or 200 mg every 2-3 weeks.

PRECAUTIONS AND WARNINGS

In the palliative treatment of breast cancer discontinue treatment if after 3 months the condition resumes or hypocalcaemia is observed in any phase of treatment.

Serum and urine calcium levels should be determined at regular intervals in women with metastatic breast carcinoma receiving testosterone.

It is generally recommended to start treatment with full doses and titrate according to individual patient characteristics.

Special precaution must be administered to patients with heart failure, hypertension; kidney failure, epilepsy; migraine, diabetes, bone metastasis; dysmenorrhea; dyslipidemia; bleeding disorders; porphyria.

oily solution for injection 10 ML VIAL

Keep out of the reach of children.

The sale only with the prescription.